Skip to main content

Advertisement

SpringerLink
Log in

Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Completeness of cytoreduction is one of the most important prognostic factors impacting outcomes of cytoreductive surgery (CRS). To what extent the surrounding normal peritoneum needs to be removed is not known. We hypothesized that the extent of peritoneal resection should be different for different tumors and performed this study to find evidence to support this rationale. To determine the extent of resection of surrounding tissue for any tumor, the mechanisms of tumor development and spread, tumor morphology, the possibility of finding disease in the surrounding normal tissue, and the pattern of lymph node metastases should be known. Surgical resections also depend on patterns of recurrence and the impact of varying extent of resection on survival. We performed a review of literature pertaining to pathways and patterns of peritoneal cancer spread to determine the scientific basis for the extent of peritonectomy. We also reviewed studies comparing less and more extensive peritoneal resection. There is no consensus on the extent of lymphadenectomy required for most PM. Based on this review, we provide recommendations for the extent of peritoneal resection and the extent of lymph node dissection that should be performed for some common peritoneal tumors and identify areas that require further research. We propose that a systematic method of synoptic reporting of pathological specimens of CRS should be developed to capture information regarding the disease distribution within the peritoneal cavity and morphology of PM from different tumors. This can in future be used to establish standard guidelines for such resections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer. 2010;116:5608–18. https://doi.org/10.1002/cncr.25356.

    Article  PubMed  Google Scholar 

  2. Rajan F, Bhatt A. Evolving role of CRS and HIPEC-Current indications. In: Bhatt A (ed) Management of peritoneal metastases: cytoreductive surgery, HIPEC and beyond. New York: Springer; 2018. p. 19–67.

  3. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer; 1996:359–74.

    Chapter  Google Scholar 

  4. Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(7):911–9.

    Article  CAS  Google Scholar 

  5. Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10:3.

    Article  Google Scholar 

  6. Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen E, et al. Positive surgical margins in the 10 most common solid cancers. Scientific Rep. 2018;8(1):5686. https://doi.org/10.1038/s41598-018-23403-5.

    Article  CAS  Google Scholar 

  7. Corsi F, Sorrentino L, Bossi D, Sartani A, Foschi D. Preoperative localization and surgical margins in conservative breast surgery. Int J Surg Oncol. 2013;2013:793–819. https://doi.org/10.1155/2013/793819.

    Article  Google Scholar 

  8. Keating JJ, Okusanya OT, De Jesus E, Judy R, Jiang J, Deshpande C, et al. Intraoperative molecular imaging of lung adenocarcinoma can identify residual tumor cells at the surgical margins. Mol Imaging Biol. 2016;18(2):209–18. https://doi.org/10.1007/s11307-015-0878-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Rocha R, Marinho R, Aparício D, Fragoso M, Sousa M, Gomes A, et al. Impact of bowel resection margins in node negative colon cancer. Springerplus. 2016;5(1):1959. https://doi.org/10.1186/s40064-016-3650-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sadot E, Groot Koerkamp B, Leal JN, Shia M, Gonen M, Allen PJ, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: Surgical technique or biologic surrogate? Ann Surg. 2005;262:476–85, (Discussion 483–5).

    Article  Google Scholar 

  11. Abdalla EK, Bauer TW, Chun YS, D’Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford). 2013;15(2):119–30. https://doi.org/10.1111/j.1477-2574.2012.00597.x.

    Article  Google Scholar 

  12. Deraco M, Kusamura S, Corbellini C, Guaglio M, Paviglianiti C, Baratti D. Treatment principles for peritoneal surface malignancies. Minerva Chir. 2016;71(2):124–45. (Epub 2016 Feb 5).

    PubMed  Google Scholar 

  13. Glehen O, Gilly FN. Quantitative prognostic indicators of peritoneal surface malignancy: carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am. 2003;12(3):649–71.

    Article  Google Scholar 

  14. Solass W, Horvath P, Struller F, Konigsrainer I, Beckert S, Kongsrainer A, et al. Functional vascular anatomy of the peritoneum in health and disease. Pleura Peritoneum. 2016;1(3):145–58. https://doi.org/10.1515/pp-2016-0015.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Baratti D, Kusamura S, Cabras AD, Laterza B, Balestra MR, Deraco M. Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2010;17(1):45–53. https://doi.org/10.1245/s10434-009-0756-2. (Epub 2009 Oct 24).

    Article  PubMed  Google Scholar 

  16. Mehta S, Bhatt A, Glehen O. Cytoreductive surgery and peritonectomy procedures. Indian J Surg Oncol. 2016;7(2):139–51. https://doi.org/10.1007/s13193-016-0505-5.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.

    Article  CAS  Google Scholar 

  18. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–11.

    Article  CAS  Google Scholar 

  19. Kusamura S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, et al. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol. 2010;2(1):12–8.

    Article  Google Scholar 

  20. Sampson J A. Implantation peritoneal carcinomatosis of ovarian origin. Am J Pathol. 1931;7:423–443.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Murphy EM, Sexton R, Moran BJ. Early results of surgery in 123 patients with pseudomyxoma peritonei from a perforated appendiceal neoplasm. Dis Colon Rectum. 2007;50:37–42.

    Article  Google Scholar 

  22. Kostic Z, Cuk V, Bokun R, Ignjatovic D, Usaj-Knezevic S, Ignjatovic M. Detection of free cancer cells in peritoneal cavity in patients surgically treated for gastric adenocarcinoma. Vojnosanit Pregl. 2006;63:349–56.

    Article  Google Scholar 

  23. Meyers M A. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med. 1973;119:198–206.

    Article  CAS  Google Scholar 

  24. Shimotsuma M, Shields JW, Simpson-Morgan MW, et al. Morpho-physiological function and role of omental milky spots as omentum associated lymphoid tissue (OALT) in the peritoneal cavity. Lymphology. 1993;26:90–101.

    CAS  PubMed  Google Scholar 

  25. Yonemura Y, Kawamura T, Bandou E, Tsukiyama G, Endou Y, Miura M. The natural history of free cancer cells in the peritoneal cavity. In: Gonzalez-Moreno S (ed) Advances in peritoneal surface oncology. Berlin: Springer, 2007:11–23.

    Chapter  Google Scholar 

  26. Yonemura Y, Endo Y, Obata T, Sasaki T. Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci. 2007;98:11–8.

    Article  CAS  Google Scholar 

  27. Carmignani CP, Sugarbaker T, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev. 2003; 22:465–72.

    Article  Google Scholar 

  28. Sugarbaker PH. Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg. 2005;18(3):190–203. https://doi.org/10.1055/s-2005-916280.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. In: Sugarbaker PH (ed) Peritoneal carcinomatosis: principles of management. Boston: Kluwer, 1995, p. 80–99.

    Google Scholar 

  30. Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24 (Suppl 10):x16–21. https://doi.org/10.1093/annonc/mdt463.

    Article  PubMed  Google Scholar 

  31. Bhatt A, Yonemura Y, Benzerdjeb N, Mehta S, Mishra S, Parikh L, et al. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential- a prospective multi-centric study. Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2019.07.019.

    Article  PubMed  Google Scholar 

  32. Deraco M, Baratti D, Kusamura S, Laterza B, Balestra MR. Surgical technique of parietal and visceral peritonectomy for peritoneal surface malignancies. J Surg Oncol. 2009;100(4):321–8. https://doi.org/10.1002/jso.21388.

    Article  PubMed  Google Scholar 

  33. Baratti D, Kusamura S, Cabras AD, Deraco M. Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study. Ann Surg Oncol. 2012;19(5):1416–24. https://doi.org/10.1245/s10434-012-2237-2.

    Article  PubMed  Google Scholar 

  34. Sinukumar S, Rajan F, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer. A study by INDEPSO. Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2019.02.031.

    Article  PubMed  Google Scholar 

  35. Bhatt A, Sinukumar S, Mehta S, Damodaran D, Zaveri S, Kammar P, et al. Patterns of pathological response to neoadjuvant chemotherapy and its clinical implications in patients undergoing interval cytoreductive surgery for advanced serous epithelial ovarian cancer: a study by the Indian Network for Development of Peritoneal Surface Oncology (INDEPSO). Eur J Surg Oncol. 2019;45(4):666–71. https://doi.org/10.1016/j.ejso.2019.01.009. (Epub 2019 Jan 9).

    Article  PubMed  Google Scholar 

  36. Sammartino P, Biacchi D, Cornali T, et al. Proactive management for gastric, colorectal and appendiceal malignancies: preventing peritoneal metastases with hyperthermic intraperitoneal chemotherapy (HIPEC). Indian J Surg Oncol. 2016;7(2):215–24.

    Article  Google Scholar 

  37. Levy AD, Shaw JC, Sobin LH. Secondary tumors and tumorlike lesions of the peritoneal cavity: imaging features with pathologic correlation. Radiographics. 2009;29(2):347–73. https://doi.org/10.1148/rg.292085189.

    Article  PubMed  Google Scholar 

  38. Hynninen J, Lavonius M, Oksa S, Grenman S, Carpen O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol. 2013;128: 229–32.

    Article  Google Scholar 

  39. Berger Y, Jacoby H, Kaufmann MI, Ben-Yaacov A, Westreich G, Sharon I, et al. Correlation between intraoperative and pathological findings for patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2019;26(4):1103–9.

    Article  CAS  Google Scholar 

  40. Yonemura Y, Canbay E, Ishibashi H, Nishino E, Endou Y, Sako S, et al. 5-Aminolevulinic acid fluorescence in detection of peritoneal metastases. Asian Pac J Cancer Prev. 2016;17(4):2271–5.

    Article  Google Scholar 

  41. Shida D, Tsukamoto S, Ochiai H, et al. Long-term outcomes after R0 resection of synchronous peritoneal metastasis from colorectal cancer without cytoreductive surgery or hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25:173. https://doi.org/10.1245/s10434-017-6133-7.

    Article  PubMed  Google Scholar 

  42. Koppe MJ, Nagtegaal ID, de Wilt JH, Ceelen WP. Recent insights into the pathophysiology of omental metastases. J Surg Oncol. 2014;110:670–5.

    Article  Google Scholar 

  43. Passot G, Kepenekian V, Vsudoyer D, Cotte E, Villeneuve L, Glehen O. Une omentectomie totale par laparotomie est indispensable pour toute chirurgie ptentiellement curative d’une carcinose peritoneale d’origine colorectal. J Cir Visc. 2019 https://doi.org/10.1016/j.jchirv.2019.03.045.

    Article  Google Scholar 

  44. Kolev V, Mironov S, Mironov O, Ishill N, Moskowitz CS, Gardner GJ, et al. Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20(6):979–84. https://doi.org/10.1111/igc.0b013e3181e833f5.

    Article  PubMed  Google Scholar 

  45. Yan TD, Brun EA, Cerruto CA, Haveric N, Chang D, Sugarbaker PH. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41–9.

    Article  Google Scholar 

  46. Borczuk AC, Taub RN, Hesdorffer M, et al. P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma. Clin Cancer Res. 2005;11:3303–8.

    Article  CAS  Google Scholar 

  47. Cerruto CA, Brun EA, Chang D, Sugarbaker PH. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma. Arch Pathol Lab Med. 2006;130:1654–61.

    PubMed  Google Scholar 

  48. Yan TD, Yoo D, Sugarbaker PH. Significance of lymph node metastasis in patents with diffuse malignant peritoneal mesothelioma. Eur J Sur Oncol. 2006;32:948–53.

    Article  CAS  Google Scholar 

  49. Kammar P, Bhatt A, Anam J, Waghoo S, Pandey J, Mehta S. Correlation between pelvic peritoneal disease and nodal metastasis in advanced ovarian cancer: can intraoperative findings define the need for systematic nodal dissection? Indian J Surg Oncol. 2019;10(Suppl 1):84–90. https://doi.org/10.1007/s13193-019-00881-1.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Somashekhar S, Ashwin K, Yethadka R, et al. Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC. Pleura Peritoneum. 2019. https://doi.org/10.1515/pp-2019-0015.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Bhatt A, Yonemura Y, Mehta S, Benjerdjeb N, Kammar P, Parikh L, et al. Target region resection in patients undergoing cytoreductive surgery for peritoneal metastases: Is it necessary in absence of visible disease? Eur J Surg Oncol. 2019. https://doi.org/10.1016/j.ejso.2019.11.495.

    Article  PubMed  Google Scholar 

  52. Jayakrishnan TT, Sharma A, Zacharias AJ, et al. Resection of the falciform ligament and ligamentum teres hepatis in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). J Sur. 2014;10(2):117–20. https://doi.org/10.7438/1584-9341-10-2-5.

    Article  Google Scholar 

  53. Sugarbaker PH, Bijelic L. The porta hepatis as a site of recurrence of mucinous appendiceal neoplasms treated by cytoreductive surgery and perioperative intraperitoneal chemotherapy. Tumori. 2008;94(5):694–700.

    Article  Google Scholar 

Download references

Funding

The authors received no funding for the study

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Zydus Hospital, Ahmedabad, India

    Aditi Bhatt MS, MCh.

  2. Department of Surgical Oncology, Centre Hospitalier Lyon-Sud, Lyon, France

    Olivier Glehen MD, PhD

Authors
  1. Aditi Bhatt MS, MCh.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olivier Glehen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olivier Glehen MD, PhD.

Ethics declarations

Disclosures

Olivier Glehen received honoraria from Gamida tech. Aditi Bhatt has no disclosures.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 68 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhatt, A., Glehen, O. Extent of Peritoneal Resection for Peritoneal Metastases: Looking Beyond a Complete Cytoreduction. Ann Surg Oncol 27, 1458–1470 (2020). https://doi.org/10.1245/s10434-020-08208-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08208-z

Search

Navigation